ATXS

About ATXS

Astria Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients and families affected by rare and niche allergic and immunological diseases. Its lead product candidate, STAR-0215, a potential monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Plasma kallikrein is an enzyme that cleaves high molecular weight kininogen (HMWK), to release bradykinin. It has four therapies for on-demand treatment of HAE: BERINERT (C1 esterase inhibitor (human)), FIRAZYR (icatibant injection), KALBITOR (ecallantide) and RUCONEST (C1 esterase inhibitor (recombinant)). Its long-term preventative treatment of HAE therapies: CINRYZE (C1 esterase inhibitor (human)), HAEGARDA (C1 esterase inhibitor subcutaneous (human)), TAKHZYRO (lanadelumab-flyo) and ORLADEYO (berotralstat).